Deutsche Bank AG Has $9.48 Million Stock Holdings in Akero Therapeutics, Inc. $AKRO

Key Points

• Deutsche Bank AG reduced its stake in Akero Therapeutics by 14.5%, selling 39,681 shares and owning 0.29% of the company worth approximately $9.48 million after the sale.
• Several large investors have recently altered their positions, with RTW Investments LP increasing their stake by 15.9% to own 6.86 million shares, valued at around $190.84 million.
• An insider, Catriona Yale, sold 10,000 shares for a total of $529,500, leading to a 9.85% decrease in their ownership, while analyst ratings on the stock have varied with a consensus rating of "Moderate Buy".

Deutsche Bank AG cut its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 14.5% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 234,130 shares of the company's stock after selling 39,681 shares during the quarter. Deutsche Bank AG owned about 0.29% of Akero Therapeutics worth $9,478,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in Akero Therapeutics in the 4th quarter valued at about $41,000. Sterling Capital Management LLC increased its stake in Akero Therapeutics by 764.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock valued at $50,000 after buying an additional 1,582 shares during the period. PNC Financial Services Group Inc. increased its stake in Akero Therapeutics by 30.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after buying an additional 390 shares during the period. Quarry LP acquired a new position in Akero Therapeutics during the 4th quarter valued at about $83,000. Finally, Amalgamated Bank increased its stake in Akero Therapeutics by 19.0% during the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company's stock valued at $104,000 after buying an additional 410 shares during the period.

Akero Therapeutics Trading Down 1.7%

Shares of Akero Therapeutics stock traded down $0.8360 during trading on Tuesday, hitting $47.7540. The stock had a trading volume of 268,510 shares, compared to its average volume of 1,414,689. The stock has a 50 day simple moving average of $51.83 and a 200 day simple moving average of $47.18. The company has a market capitalization of $3.82 billion, a PE ratio of -23.88 and a beta of -0.28. The company has a quick ratio of 12.66, a current ratio of 12.66 and a debt-to-equity ratio of 0.02. Akero Therapeutics, Inc. has a 1 year low of $21.34 and a 1 year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.11. During the same quarter in the previous year, the company earned ($0.81) earnings per share. On average, research analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Bank of America raised their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Citigroup lowered their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Cowen assumed coverage on shares of Akero Therapeutics in a research note on Monday, August 4th. They set a "buy" rating on the stock. Wall Street Zen raised shares of Akero Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, TD Cowen began coverage on shares of Akero Therapeutics in a research note on Monday, August 4th. They set a "buy" rating and a $76.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $81.57.

Insider Activity at Akero Therapeutics

In related news, COO Jonathan Young sold 12,500 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $47.79, for a total transaction of $597,375.00. Following the transaction, the chief operating officer directly owned 197,484 shares of the company's stock, valued at approximately $9,437,760.36. The trade was a 5.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Andrew Cheng sold 37,837 shares of the business's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $54.05, for a total transaction of $2,045,089.85. Following the transaction, the chief executive officer directly owned 556,487 shares in the company, valued at $30,078,122.35. The trade was a 6.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 230,406 shares of company stock valued at $12,013,920. Company insiders own 7.07% of the company's stock.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.